ProPhase Labs, Inc. (PRPH) shareholders

PRPHOTCPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026Score 0/30

$0.01−0.00 (-6.16%)

Close on Oct 19, 2026Market cap $119.68KP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions

0.0%

0M of 16M shares

Institutional holders

0 new, 0 sold out

Net institutional buying

In Q2 2026

Insider trades, 12 months

0 buys · 0 sales

Open-market trades only

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

Holder	Shares	% of class	Filing	As of
Ted Karkus	3,683,750	20.30%	13D (active) amendment	Mar 17, 2024
Venkatesan Shyam	855,102	5.50%	13G (passive)	Oct 16, 2026
ProPhase Labs, Inc.	631,195	5.00%	13G (passive) amendment	Dec 31, 2023

Top institutional holders

13F holdings as of Jun 30, 2026

Holder	Shares	% of PRPH	Value	Change	% of portfolio
Farther Finance Advisors, LLC	10	0.00%	$1	–	0.00%
CoreCap Advisors, LLC	10	0.00%	$1	–	0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

Quarter	Holders	Shares held	% of shares	New / added	Reduced / closed	Shares bought	Shares sold
Q2 2026	2	0M	0.0%	0 / 0	0 / 0	0M	0M
Q1 2026	2	0M	0.0%	0 / 1	1 / 14	0M	0M
Q4 2025	17	0M	1.3%	17 / 0	0 / 0	0M	0M

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

Name	Role	Shares owned	% of shares	Latest filing
Ted William Karkus	CEO & CHAIRMAN, Director	3,583,750	22.98%	Sep 11, 2025
Stuart Hollenshead	Chief Operating Officer	–	–	Feb 21, 2025
Carolina Abenante	Director	–	–	Nov 10, 2025
Louis Gleckel Md	Director	273,840	1.76%	Feb 18, 2025
Warren Hirsch	Director	–	–	Feb 18, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

Insider	Date	Transaction	Shares	Price	Value	Shares after
Ted William Karkus CEO & CHAIRMAN, Director, 10% owner	Apr 5, 2023	Gift	+50,000	–	–	150,000
Ted William Karkus CEO & CHAIRMAN, Director, 10% owner	Apr 5, 2023	Gift	−50,000	–	–	3,433,750
Ted William Karkus CEO & CHAIRMAN, Director, 10% owner	Apr 3, 2023	Gift	−100,000	–	–	3,483,750
Ted William Karkus CEO & CHAIRMAN, Director, 10% owner	Feb 1, 2023	Tax withholding	−268,337	$8.18	$2.19M	3,583,750
Ted William Karkus CEO & CHAIRMAN, Director, 10% owner	Feb 1, 2023	Option exercise	+500,000	$0.60	$300.00K	3,852,087
Ted William Karkus CEO & CHAIRMAN, Director, 10% owner	Jan 13, 2023	Tax withholding	−319,231	$9.36	$2.99M	3,352,087
Ted William Karkus CEO & CHAIRMAN, Director, 10% owner	Jan 13, 2023	Option exercise	+600,000	$0.60	$360.00K	3,671,318
Ted William Karkus CEO & CHAIRMAN, Director, 10% owner	Oct 16, 2022	Tax withholding	−317,291	$10.41	$3.30M	3,071,318
Ted William Karkus CEO & CHAIRMAN, Director, 10% owner	Oct 16, 2022	Option exercise	+600,000	$0.60	$360.00K	3,388,609
Ted William Karkus CEO & CHAIRMAN, Director, 10% owner	Aug 10, 2022	Tax withholding	−316,605	$10.84	$3.43M	2,788,609
Ted William Karkus CEO & CHAIRMAN, Director, 10% owner	Aug 10, 2022	Option exercise	+600,000	$0.60	$360.00K	3,105,214
Ted William Karkus CEO & CHAIRMAN, Director, 10% owner	May 23, 2022	Tax withholding	−278,257	$8.47	$2.36M	2,505,214
Ted William Karkus CEO & CHAIRMAN, Director, 10% owner	May 23, 2022	Option exercise	+450,000	$2.00	$900.00K	2,783,471
Monica L. Brady Chief Accounting Officer	May 23, 2022	Tax withholding	−11,806	$8.47	$100.00K	34,872
Monica L. Brady Chief Accounting Officer	May 23, 2022	Option exercise	+14,250	$3.18	$45.32K	46,678
Monica L. Brady Chief Accounting Officer	May 23, 2022	Option exercise	+25,000	$2.15	$53.75K	32,428
Jason Michael Barr Director	Mar 10, 2022	Buy	+721	$6.48	$4.67K	30,962
Jason Michael Barr Director	Mar 10, 2022	Buy	+750	$6.48	$4.86K	30,991
Ted William Karkus CEO & CHAIRMAN, Director, 10% owner	Jun 3, 2021	Buy	+33,943	$5.07	$172.09K	2,333,471
Ted William Karkus CEO & CHAIRMAN, Director, 10% owner	May 7, 2021	Gift	+60,000	–	–	100,000
Ted William Karkus CEO & CHAIRMAN, Director, 10% owner	May 7, 2021	Gift	−120,000	–	–	2,299,528
Ted William Karkus CEO & CHAIRMAN, Director, 10% owner	Aug 13, 2020	Sale	−50,000	$2.75	$137.50K	2,419,528
Louis Gleckel Md Director	Aug 13, 2020	Buy	+50,000	$2.75	$137.50K	273,840
Ted William Karkus CEO & CHAIRMAN, Director, 10% owner	Jul 9, 2020	Gift	+28,600	–	–	40,000
Ted William Karkus CEO & CHAIRMAN, Director, 10% owner	Jul 9, 2020	Gift	+25,550	–	–	40,000
Ted William Karkus CEO & CHAIRMAN, Director, 10% owner	Jul 9, 2020	Gift	−54,150	–	–	2,469,528
Louis Gleckel Md Director	Jul 1, 2020	Award	+7,878	$1.43	$11.27K	223,840
Jason Michael Barr Director	Jul 1, 2020	Award	+4,727	$1.43	$6.76K	30,241
Louis Gleckel Md Director	Apr 1, 2020	Award	+6,068	$1.85	$11.23K	215,962
Jason Michael Barr Director	Apr 1, 2020	Award	+3,641	$1.85	$6.74K	25,514
Ted William Karkus CEO & CHAIRMAN, Director, 10% owner	Mar 26, 2020	Sale	−100,000	$1.75	$175.00K	2,549,528
Louis Gleckel Md Director	Mar 26, 2020	Buy	+100,000	$1.75	$175.00K	209,894
Jason Michael Barr Director	Jan 1, 2020	Award	+2,782	$2.02	$5.62K	21,873
Louis Gleckel Md Director	Jan 1, 2020	Award	+5,564	$2.02	$11.24K	109,894
Louis Gleckel Md Director	Oct 1, 2019	Award	+5,740	$1.96	$11.25K	104,330
Jason Michael Barr Director	Oct 1, 2019	Buy	+2,870	$1.96	$5.63K	19,091
Jason Michael Barr Director	Aug 15, 2019	Buy	+2,500	$2.05	$5.13K	16,221
Jason Michael Barr Director	Aug 14, 2019	Buy	+6,000	$2.05	$12.30K	13,721
Louis Gleckel Md Director	Jul 1, 2019	Award	+4,727	$2.38	$11.25K	98,590
Louis Gleckel Md Director	Apr 3, 2019	Award	+3,571	$3.15	$11.25K	93,863
Louis Gleckel Md Director	Jan 2, 2019	Award	+3,583	$3.14	$11.25K	90,292
Mark A. Burnett Director	Oct 1, 2018	Award	+3,737	$3.01	$11.25K	318,282
Louis Gleckel Md Director	Oct 1, 2018	Award	+3,737	$3.01	$11.25K	86,709
Mark A. Burnett Director	Jul 19, 2018	Award	+3,737	$3.01	$11.25K	314,545
Louis Gleckel Md Director	Jul 19, 2018	Award	+3,737	$3.01	$11.25K	82,972
Ted William Karkus CEO & CHAIRMAN, Director, 10% owner	May 15, 2018	Option exercise	+150,000	$2.00	$300.00K	2,704,574
Ted William Karkus CEO & CHAIRMAN, Director, 10% owner	May 15, 2018	Option exercise	+100,000	$1.65	$165.00K	2,584,849
Ted William Karkus CEO & CHAIRMAN, Director, 10% owner	May 15, 2018	Tax withholding	−30,275	$5.45	$165.00K	2,554,574
Ted William Karkus CEO & CHAIRMAN, Director, 10% owner	May 15, 2018	Tax withholding	−55,046	$5.45	$300.00K	2,649,528
Ted William Karkus CEO & CHAIRMAN, Director, 10% owner	Dec 21, 2017	Sale	−424,789	$2.30	$977.01K	2,484,849
Ted William Karkus CEO & CHAIRMAN, Director, 10% owner	Dec 14, 2017	Option exercise	+600,000	$1.00	$600.00K	2,909,638
Robert V. Cuddihy Jr Chief Financial Officer	Sep 29, 2017	Sale	−358,621	$2.30	$824.83K	132,703
Ted William Karkus CEO & CHAIRMAN, Director, 10% owner	Sep 29, 2017	Sale	−364,950	$2.30	$839.38K	2,309,638
Braden Michael Leonard 10% owner	Sep 29, 2017	Sale	−1,695,305	$2.30	$3.90M	627,322
Jason Michael Barr Director	Sep 29, 2017	Sale	−4,379	$2.30	$10.07K	7,721
Robert V. Cuddihy Jr Chief Financial Officer	Sep 14, 2017	Option exercise	+120,000	$1.65	$198.00K	451,324
Robert V. Cuddihy Jr Chief Financial Officer	Sep 14, 2017	Option exercise	+200,000	$1.00	$200.00K	331,324
Robert V. Cuddihy Jr Chief Financial Officer	Sep 14, 2017	Option exercise	+40,000	$1.39	$55.60K	491,324
Mark S. Leventhal Director	Nov 30, 2015	Buy	+948	$1.48	$1.40K	881,980
Mark S. Leventhal Director	Nov 30, 2015	Award	+948	$1.48	$1.40K	881,980

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding

–

0M shares short

Days to cover

1.0

At 1M shares a day

Change since last report

-3.2%

From 0M shares

Short volume, 20 days

52.8%

Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of ProPhase Labs's stock actually held short. No settlement fails above the SEC's reporting threshold in the last 90 days.

Where these numbers come from

Parsed from the XBRL in ProPhase Labs's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-10.33 reverse split on Jun 1, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is PRPH.

Compare: PRPH vs PTCHF · PRPH vs IMNM · PRPH vs ANL · PRPH vs PTPI · PRPH vs APLM

Company	Revenue	Growth
IMNM	$4.02M	-63.3%
PRPH	$3.85M	-31.2%
PTCHF	–	–
ANL	–	–
PTPI	–	–
APLM	–	–

Company

Exchange: OTC
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 19
Held by institutions: 0.0%
Auditor: Fruci & Associates II, PLLC
SEC CIK: 868278

Advertisement
300 × 250

See a number that looks wrong?